James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. According to the complaint, defendants provided investors with misleading statements concerning the true state of Pylarify's competitive position; notably, that Lantheus was not equipp ...

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, inclusive (the “Class Period”), have until Monday, November 10, 2025 to seek appointment as lead plaintiff of the Lantheus class action lawsuit. Captioned Margolis v. Lantheus Holdings, Inc., No. 25-cv-07491 (S.D.N.Y.), the Lantheus class action lawsuit charges Lantheus and certain of Lantheus’ ...

Core Insights - Lantheus Holdings and GE HealthCare have entered into an exclusive licensing agreement for the development, manufacturing, and commercialization of piflufolastat F18 (PYLARIFY) in Japan for prostate cancer diagnostics [1][2] - The partnership aims to enhance the reach of PYLARIFY in international markets, particularly in Japan, which has the third highest number of prostate cancer cases globally [3][4] - GE HealthCare will leverage its manufacturing network and R&D expertise, especially following its acquisition of Nihon Medi-Physics Co., Ltd. in March 2025 [2][3] Company Overview - Lantheus is a leading radiopharmaceutical-focused company, providing solutions for nearly 70 years, with a mission to improve patient outcomes through innovative diagnostics [19] - GE HealthCare is a global healthcare solutions provider with a focus on medical technology and pharmaceutical diagnostics, serving patients and providers for over 125 years [20] Product Information - PYLARIFY is a PSMA-targeted PET imaging agent approved by the FDA in 2021, and it has been utilized in over 500,000 scans across the U.S. [4] - The product is designed to visualize lymph nodes, bone, and soft tissue metastases in men with prostate cancer, combining the accuracy of PET imaging with the precision of PSMA targeting [5] Financial Terms - Under the agreement, GE HealthCare will pay Lantheus an upfront license fee, development milestones, and tiered royalties based on product sales in Japan [2][3]

Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 23, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:Â LNTH). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LANTHEUS HOLDINGS, INC. (LNTH), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE NOVEMBER 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ON ...

LOS ANGELES--(BUSINESS WIRE)--Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – LNTH. ...

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lantheus investors who were adversely affected by alleged securities fraud between February 26, 2025 and August 5, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/lantheus-holding ...

SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lantheus Holdings, Inc. (NASDAQ: LNTH) securities between February 26, 2025 and August 5, 2025, all dates inclusive (the "Class Period"), have until November 10, 2025 to seek appointment as lead plaintiff of the Lantheus class action lawsuit. ...

NEW YORK , Sept. 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Lantheus Holdings, Inc. (NASDAQ: LNTH). ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Lantheus provided misleading statements regarding the competitive position of its product, Pylarify, while concealing material adverse facts [5]. - It is claimed that Lantheus failed to properly assess pricing and competitive dynamics, which led to a detrimental price increase in early 2025, risking the product's revenue and growth potential [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Lantheus Holdings, Inc. due to misleading statements regarding the competitive position of its product Pylarify, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Lantheus between February 26, 2025, and August 5, 2025, to discuss their legal options [1][4]. - A federal securities class action has been filed against Lantheus, with a deadline of November 10, 2025, for investors to seek the role of lead plaintiff [4][9]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Financial Performance and Stock Impact - Lantheus reported first-quarter results below market expectations on May 7, 2025, with Pylarify's performance particularly disappointing [7]. - On August 6, 2025, Lantheus announced further disappointing results, reducing growth expectations for Pylarify, which had fallen 8.3% year-over-year, and slashed fiscal year 2025 growth projections [7]. - Following these announcements, Lantheus' stock price plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in one day [8].